利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.15 秒)

    USE OF (HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES FOR THE MANUFACTURE OF MEDICAMENTS ACTIVE AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS
    5.
    发明申请
    USE OF (HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES FOR THE MANUFACTURE OF MEDICAMENTS ACTIVE AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS 审中-公开
    （HALOBENZYLOXY）苯甲酰胺丙酰胺用于制备作为钠和/或钙通道选择性调节剂活性的药物的用途

    公开(公告)号：US20110184068A1

    公开(公告)日：2011-07-28

    申请号：US12939726

    申请日：2010-11-04

    申请人： Elena Barbanti ,  Florian Thaler ,  Carla Caccia ,  Ruggero Fariello ,  Patricia Salvati

    发明人： Elena Barbanti ,  Florian Thaler ,  Carla Caccia ,  Ruggero Fariello ,  Patricia Salvati

    IPC分类号： A61K31/167 ,  A61P25/04

    CPC分类号： C07C237/06 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory processes affecting all body systems, disorders affecting skin and related tissues, disorders of the respiratory system, disorders of the immune and endocrinological systems, gastrointestinal, urogenital, metabolic and seizure disorders, where the above mechanisms have been described as playing a pathological role.

    摘要翻译： 本发明涉及选择的（R）-2 - [（卤代苄氧基）苄基氨基] - 丙酰胺及其药学上可接受的盐在制备药物中的用途，其作为钠和/或钙通道调节剂选择性活性， 预防，缓解和治愈各种病症，包括疼痛，偏头痛，周围疾病，心血管疾病，影响所有身体系统的炎症过程，影响皮肤和相关组织的疾病，呼吸系统疾病，免疫和内分泌系统疾病 ，胃肠道，泌尿生殖，代谢和发作障碍，其中上述机制被描述为发挥病理作用。

    (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
    6.
    发明申请
    (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators 审中-公开
    （Halobenzyloxy）苄基氨基 - 丙酰胺作为钠和/或钙通道选择性调节剂

    公开(公告)号：US20080096965A1

    公开(公告)日：2008-04-24

    申请号：US11574751

    申请日：2005-07-28

    申请人： Elena Barbanti ,  Florian Thaler ,  Carla Caccia ,  Ruggero Fariello ,  Partricia Salvati

    发明人： Elena Barbanti ,  Florian Thaler ,  Carla Caccia ,  Ruggero Fariello ,  Partricia Salvati

    IPC分类号： A61K31/195 ,  A61P29/00

    CPC分类号： C07C237/06 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active assodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory processes affecting all body systems, disorders affecting skin and related tissues, disorders of the respiratory system, disorders of the immune and endocrinological systems, gastrointestinal, urogenital, metabolic and seizure disorders, where the above mechanisms have been described as playing a pathological role.

    摘要翻译： 本发明涉及选择的（R）-2 - [（卤代苄氧基）苄氨基] - 丙酰胺及其药学上可接受的盐在制备药物中的用途，所述药物是选择性活性的脯氨酸和/或钙通道调节剂，因此可用于预防 ，减轻和治愈各种病症，包括疼痛，偏头痛，周围疾病，心血管疾病，影响所有身体系统的炎症过程，影响皮肤和相关组织的病症，呼吸系统疾病，免疫和内分泌系统疾病， 胃肠道，泌尿生殖，代谢和发作障碍，其中上述机制被描述为发挥病理作用。

    HYDROXYLAMINE DERIVATIVES
    7.
    发明申请
    HYDROXYLAMINE DERIVATIVES 审中-公开
    羟基胺衍生物

    公开(公告)号：US20100197799A1

    公开(公告)日：2010-08-05

    申请号：US12760007

    申请日：2010-04-14

    申请人： Carla CACCIA ,  Laura Girola ,  Petra Karin Kaltofen ,  Daniele Losi ,  Patricia Salvati ,  Enrico Selva ,  Florian Thaler

    发明人： Carla CACCIA ,  Laura Girola ,  Petra Karin Kaltofen ,  Daniele Losi ,  Patricia Salvati ,  Enrico Selva ,  Florian Thaler

    IPC分类号： A61K31/13 ,  C07C239/20 ,  A61P25/16 ,  A61P25/28

    CPC分类号： C07C239/20 ,  A61K31/13 ,  C07C239/12 ,  C07C2602/10

    摘要： This invention is related to hydroxylamino derivatives of the following general formula (I) wherein n is 0, 1 or 2; R1 and R2, independently of each other, are H, OH or OCH3; R3 is H or CH3; R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a five to seven-membered carbocyclic ring; and R5 and R6, independently of each other, are H or C1-C5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing the compounds and to pharmaceutical compositions containing them.

    摘要翻译： 本发明涉及以下通式（I）的羟基氨基衍生物，其中n为0,1或2; R 1和R 2彼此独立地是H，OH或OCH 3; R3是H或CH3; R4是H，C1-C3直链或支链烷基，或与R3一起形成五至七元碳环; 和R5和R6彼此独立地是H或C 1 -C 5直链或支链烷基及其药学上可接受的盐或前药，用于制备用于预防，治疗和诊断与蛋白质错折叠相关的CNS退行性病症的药物 和/或散乱。 本发明还涉及式（I）中包括的新化合物，涉及制备该化合物的方法和含有该化合物的药物组合物。

    N-acyl-N′-benzyl-alkylendiamino derivatives
    9.
    发明授权
    N-acyl-N′-benzyl-alkylendiamino derivatives 失效

    公开(公告)号：US07411091B2

    公开(公告)日：2008-08-12

    申请号：US10580367

    申请日：2004-11-12

    申请人： Florian Thaler ,  Cibele Maria Sabido David ,  Laura Faravelli ,  Stefania Gagliardi ,  Elena Colombo ,  Patricia Salvati

    发明人： Florian Thaler ,  Cibele Maria Sabido David ,  Laura Faravelli ,  Stefania Gagliardi ,  Elena Colombo ,  Patricia Salvati

    IPC分类号： C07C233/05 ,  C61K31/16 ,  C07D207/00

    CPC分类号： C07D207/27 ,  C07C233/36

    摘要： This invention is related to compounds and use of N-Acyl-N′-benzyl-alkylendiamino derivatives of the following general formula (I), wherein A is a straight or branched C2-C8 alkyl chain; X is a methylene, oxygen, sulphur or a NR7 group; R1 is a straight or branched C1-C8 alkyl or C3-C8 alkenylene or C3-C8 alkynylene chain, optionally substituted with CF3, phenyl, phenoxy or naphthyl, the aromatic rings optionally substituted by one or more C1-C4 alkyl, halogens, trifluoromethyl, hydroxy or C1-C4 alkoxy groups; R2, R3 are independently hydrogen, a C1-C3 alkyl chain, halogen, trifluoromethyl, hydroxy or C1-C4 alkoxy groups; R4, R5 are independently hydrogen or C1-C6 alkyl; R6 is a hydrogen or a straight or branched C1-C8 alkyl or linked to R5 can form a five to seven membered lactam; R7 is hydrogen or C1-C6 alkyl; and the pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role